Synergy Pharmaceuticals, Inc. (SGYP)

Check out top investors' recommendation for SGYP
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
7.70
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
80%/20%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Tim Chiang CRT Capital Group Buy   Nov 14, '17     7.00  Nov 14, '18  N/A 
William Tanner Lazard Capital Markets Buy   Nov 09, '17     10.00  Nov 09, '18  N/A 
William Tanner Lazard Capital Markets Buy   Sep 27, '17     11.00  Sep 27, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Sep 25, '17     8.00  Sep 25, '18  N/A 
Liav Abraham Citi Sell   Sep 13, '17     2.50  Sep 13, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Aug 10, '17     15.00  Aug 10, '18  N/A 
William Tanner Lazard Capital Markets Buy   Aug 09, '17     11.00  Aug 09, '18  N/A 
Tim Chiang CRT Capital Group Buy   Aug 01, '17     11.00  Aug 01, '18  N/A 
Tim Chiang CRT Capital Group Buy   Jun 26, '17     11.00  Jun 26, '18  N/A 
Liav Abraham Citi Sell   Apr 06, '17       Apr 06, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Jan 27, '17     18.00  Jan 27, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Jan 23, '17     11.00  Jan 23, '18  N/A 
Tim Chiang CRT Capital Group Buy   Jan 18, '17     11.00  Jan 18, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Dec 15, '16     6.50  Dec 15, '17  N/A 
Ram Selvaraju Aegis Capital Buy   Feb 29, '16   3.12  17.00  Feb 28, '17  89.74% 
Ram Selvaraju Aegis Capital Buy   Jan 25, '16   3.98  20.00  Jan 25, '17  38.94% 
Corey Davis Jefferies & Co. Buy   Nov 12, '15   5.89  19.00  Nov 12, '16  -10.19% 
Scott Henry Roth Capital Partners LLC Buy   Oct 29, '15   6.63  9.50  Oct 29, '16  -28.21% 
Ram Selvaraju Aegis Capital Buy   Oct 02, '15   6.10  20.00  Oct 02, '16  -9.67% 
Corey Davis Jefferies & Co. Buy   Sep 25, '15   5.92  19.00  Sep 25, '16  -5.24% 
< previous12